Bronchiolitis is a respiratory an infection of the small bronchi on account of respiratory syncytial virus (VRS). Annually in France, bronchiolitis impacts 30% of youngsters below 2 years outdated, that’s to say about 500,000 infants. Worldwide, bronchiolitis is chargeable for 60,000 toddler deaths per 12 months. If there’s already a preventive vaccine marketed by AstraZeneca below the identify of Synagis, it was solely reserved for infants born prematurely and youngsters at excessive threat. Sanofi and AstraZeneca have subsequently collaborated to develop a vaccine that every one infants will profit from.

Bronchiolitis vaccine: roughly 75% efficient

The vaccine developed by Sanofi and AstraZeneca is completely different from different vaccines. In impact, it’s the first passive immunizing agent injected earlier than the age of 1 12 months in infants. In apply, this preventive therapy works because of the introduction into the physique of a monoclonal antibody developed within the laboratory, right here the virus chargeable for bronchiolitis. Infants haven’t but developed an immunity able to defending themselves, this preventive therapy will enable them to guard themselves by giving them antibodies in a single dose. In its press launch, Sanofi states that: “Carried out on 1,490 infants between July 2019 and February 2021, the part 3 scientific trial of the vaccine demonstrated 74.5% efficacy towards infections (pneumonia, bronchiolitis) brought on by RSV requiring assist.” As for Jean-Francois Toussaint
International Head, Vaccine Analysis and Improvement, Sanofi, he mentioned “the favorable opinion that the CHMP issued at the moment constitutes one of the vital necessary advances when it comes to public well being and combat towards RSV for a number of a long time and has the potential to significantly alleviate the heavy bodily and psychological burden that this virus locations on households and well being methods. With this advisory, we’re effectively on our technique to reaching our objective of defending all infants towards RSV infections, with only one dose.”

Bronchiolitis: an an infection that additionally impacts the aged

Once we speak about bronchiolitis, we instantly consider younger youngsters. And but, the bronchiolitis epidemic additionally impacts the aged. Sadly, this preventive vaccine/therapy won’t be meant for this fragile public. Many laboratories are at present engaged on the event of a particular vaccine for the aged. On the official web site of the Ministry of Well being and Prevention, suggestions are revealed in an effort to restrict the transmission of the RSV virus:

  • Wash your fingers commonly ;
  • Use a hydro-alcoholic answer in the event you can’t wash your fingers;
  • Ventilate your house not less than 10 minutes a day;
  • Keep away from confined locations ;
  • Don’t share dishes;
  • Frequently clear youngsters’s toys and comforters;
  • Don’t smoke close to younger youngsters ;
  • Cowl your mouth when you have got a chilly or cough;
  • Put on a masks in case you are sick within the presence of fragile individuals;
  • Keep away from hugs with fragile individuals.

Sources

https://www.sanofi.com/fr/media-room/press-releases/2022/2022-09-16-06-00-00-2517378

https://solidarites-sante.gouv.fr/soins-et- Maladies/ Maladies/ Maladies-infectieuses/les- Maladies-de-l-hiver/article/la-bronchiolite

The editor recommends: